RXRX — RECURSION PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1601830 ·
Last close
$4.36
Market Cap
$2.33B
52W High
$7.18
52W Low
$2.77
ADV30
24,541,438
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 7,303,000 | -4,188,000 | -134,968,000 | -131,005,000 | 1,212,668,000 | 545,683,000 | 297,665,000 |
| Mar 2026 | 6,301,000 | -6,189,000 | -128,505,000 | -117,504,000 | 1,339,522,000 | 654,473,000 | 314,753,000 |
| Dec 2025 | 35,351,000 | 21,076,000 | -108,334,000 | -108,122,000 | 1,474,130,000 | 743,294,000 | 343,265,000 |
| Sep 2025 | 4,983,000 | -9,704,000 | -172,202,000 | -162,253,000 | 1,399,526,000 | 659,836,000 | 352,578,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-350,481,000
Investing CF
$-6,090,000
Financing CF
$378,609,000
CapEx
$-3,784,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,324,511,000
Inventory
—
Receivables
$14,393,000
ST Investments
—
EBIT TTM
$-521,984,000
Pretax Income TTM
$-523,465,000
Interest Exp TTM
$1,481,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$54,856,000
EBITDA
$-471,604,000
Free Cash Flow
$-219,493,744
Enterprise Value
$1,234,049,920
Total Cash
$545,683,008
Total Debt
$66,638,000
Shares Out
535,342,170
Trailing EPS
$-1.00
Book Value
$1.71
ROE
-56.6%
ROA
-27.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 74,256,000 | -648,132,000 | -644,759,000 | 1,474,130,000 | 343,265,000 | 1,130,865,000 | -371,808,000 |
| Dec 2024 | 58,488,000 | -479,004,000 | -463,661,000 | 1,448,598,000 | 413,816,000 | 1,034,782,000 | -359,174,000 |
| Dec 2023 | 43,876,000 | -350,060,000 | -328,066,000 | 653,699,000 | 190,263,000 | 463,436,000 | -287,780,000 |
| Dec 2022 | 39,681,000 | -245,727,000 | -239,476,000 | 701,288,000 | 215,482,000 | 485,806,000 | -83,524,000 |
TTM Snapshot
Revenues TTM
$66,408,000
NetIncome TTM
$-559,776,000
OpCashFlow TTM
—
Assets (Latest)
$1,339,522,000
Forward EPS
$-0.89
Max Pain — expiry 2026-10-16
max pain strike: $4.00 · spot: $4.36 · call oi: 23,548 · put oi: 4,465
Expected Move to 2026-10-16:
±$0.49
(11.35%) —
implied range
$3.87 –
$4.86
· ATM straddle on $4.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADMA | ADMA BIOLOGICS, INC. | $2.32B | $10.36 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.18B | $8.55 | — |
| NVAX | NOVAVAX INC | $2.10B | $12.75 | — |
| ALVO | Alvotech | $2.06B | $5.78 | — |
| VCEL | Vericel Corp | $2.05B | $40.10 | — |
News headlines (Yahoo Finance, 1h cache)
What Could Go Wrong With Recursion Pharmaceuticals Stock?
2026-10-08 23:58 · Yahoo
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
2026-10-06 20:50 · Yahoo
BC-Most Active Stocks
2026-10-05 14:30 · Yahoo
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
2026-09-28 20:50 · Yahoo
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
2026-09-24 15:08 · Yahoo
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
2026-09-23 19:31 · Yahoo
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
2026-09-21 01:02 · Yahoo
Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound?
2026-09-19 12:12 · Yahoo
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
2026-09-16 21:50 · Yahoo
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
2026-10-06 12:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.